2022
Compression stockings for treating vasovagal syncope (COMFORTS-II) trial: Rationale and design of a triple-blind, multi-center, randomized controlled trial
Tavolinejad H, Poopak A, Sadeghian S, Bozorgi A, Oraii A, Mollazadeh R, Emkanjoo Z, Kiarsi M, Shahabi J, Jalali A, Alaeddini F, Ariannejad H, Yadangi S, Oraii S, Kheirkhah J, Assadianrad M, Aminorroaya A, Tajdini M. Compression stockings for treating vasovagal syncope (COMFORTS-II) trial: Rationale and design of a triple-blind, multi-center, randomized controlled trial. American Heart Journal 2022, 249: 57-65. PMID: 35405100, DOI: 10.1016/j.ahj.2022.04.002.Peer-Reviewed Original ResearchConceptsElastic compression stockingsRandomized controlled trialsVasovagal syncopeProportion of participantsCompression stockingsTriple-blindLifestyle modification recommendationsVenous returnCo-primary outcomesPatient-reported adverse effectsTreat vasovagal syncopeVasovagal syncope recurrencesDiary sheetsSecondary outcomesStudy armsReduced venous returnSyncope recurrenceTrial backgroundSyncopal episodesFollow-upClinical trialsParticipantsMulti-centerOnline randomizationRecurrence
2021
Left Ventricular Pseudoaneurysm as a Complication of Myocardial Infarction; A Case Series and Review of the Literature
Ashraf H, Sadatnaseri A, Aminorroaya A, Kuhi Z, Zandi N, Karbalai Saleh S. Left Ventricular Pseudoaneurysm as a Complication of Myocardial Infarction; A Case Series and Review of the Literature. Frontiers In Emergency Medicine 2021 DOI: 10.18502/fem.v5i3.5892.Peer-Reviewed Original ResearchLeft ventricular pseudo-aneurysmComplication of myocardial infarctionMyocardial infarctionCardiac evaluation of patientsLeft ventricular pseudoaneurysmEvaluation of patientsPost operative periodHistory of MINon-invasive modalityEarly surgeryHigher mortality rateCardiac evaluationCardiac tamponadeCase seriesPseudo-aneurysmVentricular pseudoaneurysmFollow-upCardiac pathologyHemorrhagic processPseudoaneurysmRecommended managementMortality ratePatientsParietal pericardiumSurgeryComparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial
Aminorroaya A, Tavolinejad H, Sadeghian S, Jalali A, Alaeddini F, Emkanjoo Z, Mollazadeh R, Bozorgi A, Oraii S, Kiarsi M, Shahabi J, Akbarzadeh M, Rahimi B, Joharimoghadam A, Mohsenizade A, Mohammadi R, Oraii A, Ariannejad H, Apakuppakul S, Ngarmukos T, Tajdini M. Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial. American Heart Journal 2021, 237: 5-12. PMID: 33689731, DOI: 10.1016/j.ahj.2021.03.002.Peer-Reviewed Original ResearchConceptsLifestyle modificationMulti-center randomized controlled trialQuality of lifeRandomized controlled trialsVasovagal syncopeCounter-pressure maneuversImprove QoLComparison of outcomesSecondary outcomesSyncopal episodesControlled trialsPrimary outcomeQoLRecurrence of vasovagal syncopeTrial backgroundAdverse drug reactionsSurvey questionnaireTreatment of vasovagal syncopeMinor adverse drug reactionsBackground of lifestyle modificationFollow-upCOMFORT trialsTreat syncopeMedicationOutcomesHow Stable Ischemic Heart Disease Leads to Acute Coronary Syndrome in COVID-19?
Shafeghat M, Aminorroaya A, Rezaei N. How Stable Ischemic Heart Disease Leads to Acute Coronary Syndrome in COVID-19? Acta BioMedica 2021, 92: e2021512. PMID: 34738559, PMCID: PMC8689303, DOI: 10.23750/abm.v92i5.12013.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeCoronary artery diseaseStable coronary artery diseaseCoronary syndromeProgression to acute coronary syndromesCytotoxic T-cell lymphocytesIncidence of myocardial injuryOut-of-hospital cardiac arrestStable ischemic heart diseaseProgression of stable coronary artery diseaseIncreased mortality risk of patientsRate of out-of-hospital cardiac arrestMalignant ventricular arrhythmiasT-cell lymphocytesMortality risk of patientsRisk of patientsIschemic heart diseaseWorld Health Organization protocolCOVID-19 patientsIncreased mortality riskVentricular arrhythmiasSystemic inflammationCardiac arrestCytokine releaseFollow-up
2020
Comparison of trinitroglycerin and adenosine as provocative agents for head-up tilt test in patients with unexplained syncope: a semi-crossover randomized clinical trial with prospective follow-up
Tajdini M, Aminorroaya A, Rahimi B, Mortazavi S, Vasheghani Farahani A, Sadeghian S, Easapour Moghadam M, Soltani D, Bozorgi A. Comparison of trinitroglycerin and adenosine as provocative agents for head-up tilt test in patients with unexplained syncope: a semi-crossover randomized clinical trial with prospective follow-up. Journal Of Interventional Cardiac Electrophysiology 2020, 60: 31-39. PMID: 31907833, DOI: 10.1007/s10840-019-00652-6.Peer-Reviewed Original ResearchConceptsTransient loss of consciousnessFollow-upUnexplained syncopeProvocative agentsTilt testDiagnostic evaluationPositive response to HUTTHead-up tilt testResponse to HUTTSuspected vasovagal syncopeRandomized clinical trialsDiagnosis of unexplained syncopeStatistically significant differenceDiagnostic yieldLoss of consciousnessRandomized patientsEvaluating patientsVasovagal syncopeVasovagal responseClinical trialsIntravenous ADPatientsSyncopeTrinitroglycerinRe-admission
2019
Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial
Pourhosseini H, Lashkari R, Aminorroaya A, Soltani D, Jalali A, Tajdini M. Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial. IJC Heart & Vasculature 2019, 22: 96-101. PMID: 30671535, PMCID: PMC6328087, DOI: 10.1016/j.ijcha.2018.12.003.Peer-Reviewed Original ResearchGroup AGroup BElective PCIPatients of group ACompared to group BAssociated with worse outcomesElective percutaneous coronary interventionHigh dose atorvastatinMedian follow-upElevated cardiac enzymesSensitivity troponin THigh-dose treatmentOccurrence of MACEPretreatment of patientsProportional hazards regression modelsMajor cardiovascular eventsHazards regression modelsPercutaneous coronary interventionDose atorvastatinCardiac enzymesDaily dosageStable anginaWorse outcomesCardiovascular eventsFollow-up